SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-086420
Filing Date
2020-07-24
Accepted
2020-07-24 16:05:33
Documents
8
Period of Report
2020-07-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2025451d1_8k.htm 8-K 24216
2 EXHIBIT 1.1 tm2025451d1_ex1-1.htm EX-1.1 181262
3 EXHIBIT 5.1 tm2025451d1_ex5-1.htm EX-5.1 10223
4 EXHIBIT 99.1 tm2025451d1_ex99-1.htm EX-99.1 14903
5 EXHIBIT 99.2 tm2025451d1_ex99-2.htm EX-99.2 14427
6 GRAPHIC tm2025451d1_ex5-1img001.jpg GRAPHIC 2775
7 GRAPHIC tm2025451d1_ex99-1img001.jpg GRAPHIC 17854
8 GRAPHIC tm2025451d1_ex99-2img001.jpg GRAPHIC 4730
  Complete submission text file 0001104659-20-086420.txt   281748
Mailing Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850
Business Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850 240-864-2600
CASI Pharmaceuticals, Inc. (Filer) CIK: 0000895051 (see all company filings)

IRS No.: 581959440 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-20713 | Film No.: 201047003
SIC: 2836 Biological Products, (No Diagnostic Substances)